Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1992 1
1999 1
2005 2
2006 1
2007 3
2008 3
2009 9
2010 9
2011 9
2012 7
2013 5
2014 6
2015 4
2016 2
2017 8
2018 14
2019 16
2020 11
2021 10
2022 7
2023 12
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Results by year

Filters applied: . Clear all
Page 1
Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines.
Wirth A, Mikhaeel NG, Aleman BMP, Pinnix CC, Constine LS, Ricardi U, Illidge TM, Eich HT, Hoppe BS, Dabaja B, Ng AK, Kirova Y, Berthelsen AK, Dieckmann K, Yahalom J, Specht L. Wirth A, et al. Int J Radiat Oncol Biol Phys. 2020 Aug 1;107(5):909-933. doi: 10.1016/j.ijrobp.2020.03.019. Epub 2020 Apr 7. Int J Radiat Oncol Biol Phys. 2020. PMID: 32272184 Free article. Review.
Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.
Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, Schinagl D, Oei B, Rodenhuis C, Horiot JC, Struikmans H, Van Limbergen E, Kirova Y, Elkhuizen P, Bongartz R, Miralbell R, Morgan D, Dubois JB, Remouchamps V, Mirimanoff RO, Collette S, Collette L; European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups. Bartelink H, et al. Lancet Oncol. 2015 Jan;16(1):47-56. doi: 10.1016/S1470-2045(14)71156-8. Epub 2014 Dec 9. Lancet Oncol. 2015. PMID: 25500422 Clinical Trial.
Median follow-up was 17.2 years (IQR 13.0-19.0). 20-year overall survival was 59.7% (99% CI 56.3-63.0) in the boost group versus 61.1% (57.6-64.3) in the no boost group, hazard ratio (HR) 1.05 (99% CI 0.92-1.19, p=0.323). Ipsilateral breast tumour recurrence was the first …
Median follow-up was 17.2 years (IQR 13.0-19.0). 20-year overall survival was 59.7% (99% CI 56.3-63.0) in the boost group versus 61.1% (57.6 …
Qualitative indicators of milk of Simmental and Holstein cows in different seasons of lactation.
Khastayeva AZ, Zhamurova VS, Mamayeva LA, Kozhabergenov AT, Karimov NZ, Muratbekova KM. Khastayeva AZ, et al. Vet World. 2021 Apr;14(4):956-963. doi: 10.14202/vetworld.2021.956-963. Epub 2021 Apr 21. Vet World. 2021. PMID: 34083946 Free PMC article.
MATERIALS AND METHODS: In total, 80 milk samples (40 Simmental and 40 Holstein) were analyzed from LLP "Kirova" of Pavlodar region (Simmental breed) and JSC "Astana-Onim" of Akmola region (Holstein breed) in the Republic of Kazakhstan. ...RESULTS: The Simmental cows had th …
MATERIALS AND METHODS: In total, 80 milk samples (40 Simmental and 40 Holstein) were analyzed from LLP "Kirova" of Pavlodar region (S …
Pediatric Plasma Cell Neoplasms: A Population-Based Study.
Loap P, Vignon M, Bouscary D, Kirova Y. Loap P, et al. Clin Lymphoma Myeloma Leuk. 2022 Nov;22(11):841-846. doi: 10.1016/j.clml.2022.07.003. Epub 2022 Jul 11. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35941071

Hispanic patients represented 50% of the pediatric plasma cell neoplasm cases (but only 11.1% of adult cases, P < .01). Female-to-Male ratio was 1.36. Five-year overall survival rates were 88.2% (95% confidence interval [95% CI]: 74.2%-100%) for pediatric plasmacytoma a

…

Hispanic patients represented 50% of the pediatric plasma cell neoplasm cases (but only 11.1% of adult cases, P < .01). Female-to-

…
International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
Binkley MS, Flerlage JE, Savage KJ, Akhtar S, Steiner R, Zhang XY, Dickinson M, Prica A, Major A, Hendrickson PG, Hopkins D, Ng A, Casulo C, Baron J, Roberts KB, Al Kendi J, Balogh A, Ricardi U, Torka P, Specht L, De Silva R, Pickard K, Blazin LJ, Henry M, Smith CM, Halperin D, Brady J, Brennan B, Senchenko MA, Reeves M, Hoppe BS, Terezakis S, Talaulikar D, Picardi M, Kirova Y, Fergusson P, Hawkes EA, Lee D, Doo NW, Barraclough A, Cheah CY, Ku M, Hamad N, Mutsando H, Gilbertson M, Marconi T, Viiala N, Maurer MJ, Eichenauer DA, Hoppe RT; GLOW Consortium. Binkley MS, et al. J Clin Oncol. 2024 Mar 26:JCO2301655. doi: 10.1200/JCO.23.01655. Online ahead of print. J Clin Oncol. 2024. PMID: 38531001
On MVA, IAPs were not associated with PFS or OS, but IAP E had higher risk of transformation (hazard ratio [HR], 1.81; P < .05). We developed the LP-IPS with 1 point each for age 45 years, stage III-IV, hemoglobin <10.5 g/dL, and splenic involvement. ...

On MVA, IAPs were not associated with PFS or OS, but IAP E had higher risk of transformation (hazard ratio [HR], 1.81; P < .05). W

…
Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma.
Tille JC, Vieira AF, Saint-Martin C, Djerroudi L, Furhmann L, Bidard FC, Kirova Y, Tardivon A, Reyal F, Carton M, Vincent-Salomon A. Tille JC, et al. Mod Pathol. 2020 Nov;33(11):2198-2207. doi: 10.1038/s41379-020-0561-9. Epub 2020 May 13. Mod Pathol. 2020. PMID: 32404955 Free article.
Similar results were observed for iDFS (p = 0.004 for Cox univariate and p = 0.005 for log-rank test). ...Prominent nucleoli was the only nuclear feature associated with poor OS (p = 0.05) and iDFS (p = 0.05) in univariate Cox survival analysis. ...
Similar results were observed for iDFS (p = 0.004 for Cox univariate and p = 0.005 for log-rank test). ...Prominent nucleoli w …
Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature.
Kirova YM, Savignoni A, Sigal-Zafrani B, de La Rochefordiere A, Salmon RJ, This P, Asselain B, Stoppa-Lyonnet D, Fourquet A. Kirova YM, et al. Breast Cancer Res Treat. 2010 Feb;120(1):119-26. doi: 10.1007/s10549-009-0685-6. Epub 2009 Dec 24. Breast Cancer Res Treat. 2010. PMID: 20033769 Review.

Tumours in mutation carriers were more likely to be grade III (P < 10(-4)) and oestrogen receptor negative (P = 0.005) than in non-carriers and controls. ...There was no significant difference in ipsilateral tumours between mutation carriers, non-carriers and con

…

Tumours in mutation carriers were more likely to be grade III (P < 10(-4)) and oestrogen receptor negative (P = 0.005) than

…
Telemedical cardiac risk assessment by implantable cardiac monitors in patients after myocardial infarction with autonomic dysfunction (SMART-MI-DZHK9): a prospective investigator-initiated, randomised, multicentre, open-label, diagnostic trial.
Bauer A, Sappler N, von Stülpnagel L, Klemm M, Schreinlechner M, Wenner F, Schier J, Al Tawil A, Dolejsi T, Krasniqi A, Eiffener E, Bongarth C, Stühlinger M, Huemer M, Gori T, Wakili R, Sahin R, Schwinger R, Lutz M, Luik A, Gessler N, Clemmensen P, Linke A, Maier LS, Hinterseer M, Busch MC, Blaschke F, Sack S, Lennerz C, Licka M, Tilz RR, Ukena C, Ehrlich JR, Zabel M, Schmidt G, Mansmann U, Kääb S, Rizas KD, Massberg S; SMART-MI-DZHK9 investigators. Bauer A, et al. Lancet Digit Health. 2022 Feb;4(2):e105-e116. doi: 10.1016/S2589-7500(21)00253-3. Lancet Digit Health. 2022. PMID: 35090674 Free article. Clinical Trial.
During median follow-up of 21 months, serious arrhythmic events were detected in 60 (30%) patients of the implantable cardiac monitor group and 12 (6%) patients of the control group (hazard ratio 6.33 [IQR 3.40-11.78]; p<0.001). An improved detection rate by implantable …
During median follow-up of 21 months, serious arrhythmic events were detected in 60 (30%) patients of the implantable cardiac monitor group …
124 results